Key Insights

The European Continuous Glucose Monitoring (CGM) market is experiencing robust growth, projected to reach €2.04 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 11.33% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of diabetes, particularly Type 1 and Type 2, across major European nations like Germany, France, the UK, and Italy, is a significant driver. Furthermore, technological advancements leading to smaller, more accurate, and user-friendly CGM devices are boosting market adoption. Improved data integration with mobile apps and telehealth platforms enhances patient convenience and allows for better remote monitoring, contributing to the growth trajectory. The rising awareness of the benefits of proactive diabetes management and the associated reduction in long-term complications also plays a crucial role. Competitive landscape analysis reveals that major players like Medtronic, Abbott, Dexcom, and Senseonics are actively engaged in innovation and market penetration strategies, including strategic partnerships and product launches. This competitive dynamism is expected to further fuel market growth.

Looking ahead, the CGM market in Europe is poised for continued expansion. The aging population, coupled with an increasingly sedentary lifestyle and rising obesity rates, will continue to drive the demand for effective diabetes management solutions. The increasing reimbursement coverage for CGM systems by healthcare providers across various European countries will also contribute significantly to market growth. However, potential restraints include the relatively high cost of CGM devices, which might limit accessibility for some patients, and the need for ongoing sensor replacements. Nevertheless, the overall outlook remains positive, driven by the aforementioned growth drivers, suggesting a considerable expansion of the European CGM market over the forecast period. Market segmentation within the CGM market, particularly between sensors and durable devices, will also influence growth trajectories, with the sensor segment likely experiencing faster growth due to its consumable nature.

This comprehensive report provides an in-depth analysis of the Europe Continuous Glucose Monitoring (CGM) market, covering the period from 2019 to 2033. With a focus on market structure, dynamics, key players, and future trends, this report is an essential resource for industry professionals, investors, and researchers seeking actionable insights into this rapidly evolving sector. The report uses 2025 as its base and estimated year, with a forecast period spanning 2025-2033 and a historical period covering 2019-2024. Key players analyzed include Medtronic, Abbott, Dexcom, Senseonics, Ascensia, and an "Other Company Share Analysis" segment. The market is segmented by Continuous Glucose Monitoring: Sensors and Durables.

Europe Continuous Glucose Monitoring Market Structure & Innovation Trends

The European CGM market exhibits a moderately concentrated structure, with Medtronic, Abbott, and Dexcom holding significant market share in 2025. The "Other Company Share Analysis" segment accounts for xx% of the market, highlighting the presence of numerous smaller players and the potential for increased competition. Market concentration is expected to remain relatively stable over the forecast period, with the top three players maintaining their dominance through ongoing innovation and strategic acquisitions.

Key Metrics:

• Market Share (2025): Medtronic: xx%, Abbott: xx%, Dexcom: xx%, Other: xx%
• M&A Activity (2019-2024): Total deal value estimated at €xx Million. Notable deals include [Insert details of any significant M&A activity if available, otherwise state "Data not available"].

Innovation drivers include the development of advanced sensor technologies, improved data analytics capabilities, and integration with mobile health applications. The regulatory framework, primarily guided by CE marking, plays a significant role in shaping market access and product approvals. Product substitutes, such as traditional blood glucose meters, are expected to face declining market share as CGM technologies offer greater convenience and clinical benefits. The end-user demographics are largely comprised of individuals with type 1 and type 2 diabetes, with an increasing proportion of younger patients adopting CGM technology.

Europe Continuous Glucose Monitoring Market Dynamics & Trends

The European CGM market is experiencing robust growth, driven by several key factors. The increasing prevalence of diabetes, particularly type 1, coupled with rising healthcare expenditures and a growing awareness of the benefits of continuous glucose monitoring are major contributors. Technological advancements, such as the development of smaller, more accurate, and less invasive sensors, are fueling market expansion. Consumer preferences are shifting towards non-invasive monitoring technologies and user-friendly devices providing seamless data integration with smartphones and other health management systems. The competitive landscape is dynamic, with leading companies investing heavily in R&D and engaging in strategic partnerships to expand their market reach.

Key Metrics:

• CAGR (2025-2033): xx%
• Market Penetration (2025): xx%

Dominant Regions & Segments in Europe Continuous Glucose Monitoring Market

Germany, the UK, and France represent the leading markets within Europe, driven by higher diabetes prevalence, well-established healthcare infrastructure, and favorable reimbursement policies. The sensors segment currently holds a larger market share compared to the durables segment due to the recurring nature of sensor replacements. However, both segments are expected to demonstrate considerable growth throughout the forecast period.

Key Drivers for Dominant Regions:

• Germany: Strong healthcare infrastructure, high diabetes prevalence, robust reimbursement policies.
• UK: High diabetes prevalence, increasing adoption of advanced technologies, government initiatives focused on diabetes management.
• France: Growing awareness of CGM benefits, increasing investment in healthcare technology.

Segment Analysis:

The Sensors segment is characterized by strong growth due to the recurring nature of sensor replacements, while the Durables segment experiences steady growth driven by the ongoing adoption of advanced CGM systems.

Europe Continuous Glucose Monitoring Market Product Innovations

Recent advancements in CGM technology have focused on improving accuracy, reducing the invasiveness of insertion procedures, extending sensor lifespan, and enhancing user-friendliness through integration with mobile applications. These innovations aim to overcome some of the current limitations associated with CGM systems, such as the need for calibration and potential sensor failures. Market fit is increasingly influenced by patient convenience and seamless data integration with other digital health solutions. The introduction of Medtronic's Simplera, a disposable CGM for individuals aged 2 and above, exemplifies the trend towards simplified designs and improved usability.

Report Scope & Segmentation Analysis

This report analyzes the European CGM market across two key segments: Sensors and Durables. The Sensors segment includes various types of CGM sensors, differing in size, lifespan, accuracy, and invasiveness. This segment is characterized by high recurring revenue due to the need for regular sensor replacements. The Durables segment comprises the CGM devices themselves, including transmitters, receivers, and associated accessories. Growth in this segment is driven by increasing adoption of CGM technology and continuous improvements in device features. Competitive dynamics within each segment involve innovation, pricing strategies, and distribution channels.

Key Drivers of Europe Continuous Glucose Monitoring Market Growth

Several factors contribute to the growth of the European CGM market. The rising prevalence of diabetes is a primary driver, with a significant portion of the population requiring effective glucose monitoring. Technological advancements, like improved sensor accuracy and smaller device sizes, enhance patient compliance. Favorable reimbursement policies in several European countries are making CGM more accessible and affordable. Finally, growing awareness among healthcare professionals and patients regarding the benefits of CGM is driving wider adoption.

Challenges in the Europe Continuous Glucose Monitoring Market Sector

Despite the significant growth potential, the European CGM market faces challenges. High costs associated with CGM systems can limit access for some patients, especially in countries with limited healthcare coverage. The need for regular calibration and potential sensor malfunctions can be frustrating for users and affect accuracy. Supply chain disruptions may also cause delays in delivering the supplies necessary to manage this condition. The competitive landscape presents additional pressure for companies to innovate and differentiate their offerings.

Emerging Opportunities in Europe Continuous Glucose Monitoring Market

The European CGM market presents several emerging opportunities. Expansion into underserved patient populations, particularly those in less developed regions, offers significant potential. The integration of CGM data with other digital health platforms for personalized diabetes management is another promising area. Furthermore, technological innovation, such as the development of implantable sensors and improved data analytics, could revolutionize the industry.

Leading Players in the Europe Continuous Glucose Monitoring Market Market

• Medtronic
• Abbott
• Other Company Share Analyse
• Dexcom
• Senseonics
• Ascensia

Key Developments in Europe Continuous Glucose Monitoring Market Industry

• October 2023: Medtronic launches Simplera, a cutting-edge disposable CGM for individuals with diabetes aged 2 and above, currently undergoing FDA evaluation. This launch signifies a shift towards more user-friendly and accessible CGM technology.
• June 2022: Ascensia Diabetes Care's partner, Senseonics Holdings, Inc., receives CE Mark approval for the Eversense E3 CGM System, expanding market access within the EU. This development increases competition and offers patients more choices.

Future Outlook for Europe Continuous Glucose Monitoring Market Market

The future of the European CGM market appears bright, with continued growth driven by technological advancements, increasing diabetes prevalence, and supportive regulatory environments. Strategic partnerships, mergers and acquisitions, and expansion into new markets will shape the competitive landscape. Focus on improved data analytics, integration with other healthcare technologies, and expansion to new patient populations will unlock substantial growth opportunities in the coming years.

Europe Continuous Glucose Monitoring Market Segmentation

• 1. Continuous Glucose Monitoring
  • 1.1. Sensors
  • 1.2. Durables

Europe Continuous Glucose Monitoring Market Segmentation By Geography

• 1. France
• 2. Germany
• 3. Italy
• 4. Spain
• 5. Russia
• 6. United Kingdom
• 7. Rest of Europe